Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scot...
Read moreA new game changing treatment for people with multiple myeloma will now be available on the NHS in E...
Read moreConclusion: Blincyto has significant clinical benefits, but that further evidence on cost-effective...
Read moreUnderstanding payer value and evidence requirements to secure pricing and reimbursement for a novel ...
Read moreAt the current rate, annual deaths due to AMR is expected to reach 10 million by 2050 globally, with...
Read moreThis study investigates the efficiency of the new CDF appraisal process for indications without prio...
Read moreThis study investigates NICE's evaluation of existing CDF treatments and its potential impact on fun...
Read moreIncluded in this issue is the implications for the UK market regarding Brexit and how the UKs CDF pe...
Read moreThis process aims to be completely transparent , to enable faster patient access to oncology treatme...
Read moreBoth payers and physicians do not believe that at the current prices Praluent and Repatha offer sign...
Read more